Dr Reddy's Laboratories Limited announced on Tuesday that it has launched Bivalirudin injection, an anti-coagulant drug, to be available for use in 250-mg vials in the United States of America (US).
Product to be available in packages of 10 single-dose vials.
The new drug, which is is a generic equivalent of Angiomax, has gained the approval of the US Food and Drug Administration (USFDA), thereby, its enrty in the US market.
According to IMS health data, Angiomax brand and generic versions of the anti-coagulant drug clocked sales of approximately $198 million in US in FY17.